Dr. Mel Spigelman

Venture Partner

  • Medical Doctor and Professor of Internal Medicine & Oncology
  • Joined Wellington in 2005
  • Former VP R&D USA at BASF Pharma
  • Since 2003 Director R&D and since 2009 CEO of The Global Alliance for TB Drug Development, N.Y.



Dr. Mel Spigelman joined the Wellington Partners Life Science team as a Venture Partner in 2005. He advises on clinical development, regulatory affairs and strategic decisions.

Dr. Melvin Spigelman is President and CEO of the Global Alliance for TB Drug Development, NY (USA). He also serves on the Coordinating Board of the WHO Stop TB Partnership, where he is Co-Chair of the Working Group on New Drugs, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.

In addition, Dr. Spigelman served as board member of several private and publicly listed biotech companies including The Medicines Company (acquired by Novartis). Prior to joining the TB Alliance, he was with BASF Pharma Knoll AG for 13 years in leading R&D positions (Global Head of Clinical Development, Head R&D USA). He holds a Doctor of Medicine degree from the Mount Sinai School of Medicine, NY (USA), where he also worked as an Assistant Professor.